Lab No. : PHL/25-06-2024/SR9282666 Lab Add.

: Newtown,Kolkata-700156

Patient Name : JHARNA MAJUMDAR Ref Dr. : Dr.MEDICAL OFFICER

Age : 67 Y 10 M 17 D Collection Date : 25/Jun/2024 08:14AM

Gender :F Report Date : 25/Jun/2024 11:00AM

DEPARTMENT OF BIOCHEMISTRY
Test Name Result Bio Ref. Interval Unit

GLUCOSE,FASTING , BLOOD, NAF PLASMA 118 Impaired Fasting-100-125 mg/dL

(Method:Gluc Oxidase Trinder) .~Diabetes- >= 126.~Fasting is
defined as no caloric intake for at
least 8 hours.

In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

Reference :
ADA Standards of Medical Care in Diabetes – 2020. Diabetes Care Volume 43, Supplement 1.

CREATININE, BLOOD 0.97 0.5-1.1 mg/dL

(Method:Jaffe, alkaline picrate, kinetic)

*** End Of Report ***

Page 1 of 3
 Lab No. : PHL/25-06-2024/SR9282666 Lab Add. : Newtown,Kolkata-700156

Patient Name : JHARNA MAJUMDAR Ref Dr. : Dr.MEDICAL OFFICER

Age : 67 Y 10 M 17 D Collection Date : 25/Jun/2024 08:12AM

Gender :F Report Date : 25/Jun/2024 11:39AM

DEPARTMENT OF BIOCHEMISTRY
Test Name Result Bio Ref. Interval Unit

GLYCATED HAEMOGLOBIN (HBA1C) , EDTA WHOLE BLOOD

GLYCATED HEMOGLOBIN (HBA1C) 6.6 ***FOR BIOLOGICAL REFERENCE %
INTERVAL DETAILS , PLEASE
REFER TO THE BELOW
MENTIONED REMARKS/NOTE
WITH ADDITIONAL CLINICAL
INFORMATION ***
HbA1c (IFCC) 48.0 mmol/mol
(Method:HPLC)

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Low risk / Normal / non-diabetic : <5.7% (NGSP) / < 39 mmol/mol (IFCC)
Pre-diabetes/High risk of Diabetes : 5.7%- 6.4% (NGSP) / 39 - < 48 mmol/mol (IFCC)
Diabetics-HbA1c level : >/= 6.5% (NGSP) / > 48 mmol/mol (IFCC)

Analyzer used :- Bio-Rad-VARIANT TURBO 2.0

Method : HPLC Cation Exchange

Recommendations for glycemic targets

Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
Ø For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease .
Action suggested >8% as it indicates poor control.
Ø Some patients may benefit from HbA1c goals that are stringent.
Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after
surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B12/ folate deficiency, presence of chronic renal or liver
disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.
Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8
References:
1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online
1 March 2016. doi:10.7326/M15-3016.
2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC
Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

PDF Attached

*** End Of Report ***

Lab No. : PHL/25-06-2024/SR9282666 Page 2 of 3

 Lab No. : PHL/25-06-2024/SR9282666 Lab Add. : Newtown,Kolkata-700156

Patient Name : JHARNA MAJUMDAR Ref Dr. : Dr.MEDICAL OFFICER

Age : 67 Y 10 M 17 D Collection Date : 25/Jun/2024 08:08AM

Gender :F Report Date : 25/Jun/2024 11:05AM

DEPARTMENT OF HAEMATOLOGY
Test Name Result Bio Ref. Interval Unit

ESR (ERYTHROCYTE SEDIMENTATION RATE) , EDTA WHOLE BLOOD

1stHour 17 0.00 - 20.00 mm/hr mm/hr
(Method:Westergren)

CBC WITH PLATELET (THROMBOCYTE) COUNT , EDTA WHOLE BLOOD

HEMOGLOBIN 13.0 12 - 15 g/dL
(Method:PHOTOMETRIC)
WBC 6.4 4 - 10 *10^3/µL
(Method:DC detection method)
RBC 4.53 3.8 - 4.8 *10^6/µL
(Method:DC detection method)
PLATELET (THROMBOCYTE) COUNT 160 150 - 450*10^3 *10^3/µL
(Method:DC detection method/Microscopy)
DIFFERENTIAL COUNT
NEUTROPHILS 68 40 - 80 % %
(Method:Flowcytometry/Microscopy)
LYMPHOCYTES 20 20 - 40 % %
(Method:Flowcytometry/Microscopy)
MONOCYTES 07 2 - 10 % %
(Method:Flowcytometry/Microscopy)
EOSINOPHILS 04 1-6% %
(Method:Flowcytometry/Microscopy)
BASOPHILS 01 0-0.9% %
(Method:Flowcytometry/Microscopy)
CBC SUBGROUP
HEMATOCRIT / PCV 39.9 36 - 46 % %
(Method:Calculated)
MCV 88.1 83 - 101 fl fl
(Method:Calculated)
MCH 28.6 27 - 32 pg pg
(Method:Calculated)
MCHC 32.5 31.5-34.5 gm/dl gm/dl
(Method:Calculated)
RDW - RED CELL DISTRIBUTION WIDTH 16.1 11.6-14% %
(Method:Calculated)
PDW-PLATELET DISTRIBUTION WIDTH 35.2 8.3 - 25 fL fL
(Method:Calculated)
MPV-MEAN PLATELET VOLUME 14.5 7.5 - 11.5 fl
(Method:Calculated)

Lab No. : PHL/25-06-2024/SR9282666 Page 3 of 3

SURAKSHA DIAGNOSTIC,RAJARHAT,KOLKATA PATIENT REPORT
BIO-RAD VARIANT-II TURBO CDM5.4. SN-16122 V2TURBO_A1c_2.0

Patient Data Analysis Data

Sample ID: D02135712000 Analysis Performed: 25/JUN/2024 11:04:19
Patient ID: SR9282666 Injection Number: 821U
Name: Run Number: 13
Physician: Rack ID: 0004
Sex: Tube Number: 3
DOB: Report Generated: 25/JUN/2024 11:18:54
Operator ID: ANUP
Comments:

NGSP Retention Peak

Peak Name % Area % Time (min) Area
A1a --- 1.1 0.163 24659
A1b --- 1.9 0.230 44019
LA1c --- 2.2 0.405 52465
A1c 6.6* --- 0.509 130551
P3 --- 4.0 0.787 94718
P4 --- 1.4 0.866 31822
Ao --- 83.9 0.973 1968559

*Values outside of expected ranges Total Area: 2,346,792

HbA1c (NGSP) = 6.6* % HbA1c (IFCC) = 48* mmol/mol

20.0

17.5

15.0

12.5
%A1c

0.51

10.0
A1c -

0.79

7.5
0.40

0.87
-
0.23

5.0
0.16

-
-

2.5
-

0.97

0.0
-

0.00 0.25 0.50 0.75 1.00 1.25 1.50

Time (min.)